An AI-enabled automated image analysis method to quantitatively score membrane-bound TROP2 shows that TROP2 QCS-NMR positivity is predictive of longer PFS in lung cancer.
“AI-enabled automated image analysis to quantitatively score how much TROP2 is membrane-bound, relative to the total TROP2. TROP2 QCS-NMR positivity is predictive of longer PFS in lung cancer.”
— @antgiorda · TROP2 Biomarker Analysis · View post ↗
“⭐️Fantastic talk on “ADC’s in lung cancer” by the terrific @VamsiVelcheti at the STOP cancer summit @MiteshBorad @OncoAlert”
— @VivekSubbiah · ADCs in Lung Cancer · View post ↗An analysis of the NSABP B-41 trial found that AI-based Tumor-Infiltrating Lymphocyte (TIL) assessment was associated with pathological complete response (pCR) in early HER2-positive breast cancer. Separately, a randomized clinical trial investigated electronic patient-reported outcome monitoring with alert-based interventions for patients with metastatic breast cancer. Discussion also touched on the role of one-week regional nodal radiotherapy in maintaining quality of life for patients with early-stage disease.
“AI-based TIL assessment was associated with pCR across ER subtypes and may complement manual TIL scoring”
— @IlanaSchlam · AI-based TILs in HER2+ Breast Cancer · View post ↗📌 Amplified by @KolPulseAI
“Electronic Patient-Reported Outcome Monitoring With Alert-Based Interventions in Metastatic Breast #Cancer: A Randomized Clinical Trial.”
— @RyanNipp · ePRO Monitoring in MBC · View post ↗
“One-Week Regional Nodal Radiotherapy Maintains Quality of Life in Breast Cancer Patients”
— @Applied_RadOnc · Regional Nodal Radiotherapy · View post ↗The new BEACON-HCC treatment allocation system for hepatocellular carcinoma reclassifies some disease, with portal vein thrombosis (VP1/2) no longer considered "advanced disease," and incorporates SBRT and Y90. Additionally, three foundational papers in *Nature* detail new patient-derived 3D cancer models that show high genomic concordance (97.8%) with original tumors and have uncovered new biological insights, such as allele-specific KRAS dependency in colorectal cancer.
“Taken together, these studies move cancer dependency mapping closer to the biology of actual human tumors. The model matters—and so does the environment in which we study it.”
— @DrChoueiri · 3D Cancer Models · View post ↗
“➡️BEACON-HCC is a new HCC treatment allocation system for #HCC, developed by @HCCLIVEConf consortium There are MANY differences vs BCLC but perhaps most significant, VP1/2 is no longer considered "advanced disease"”
— @MarkYarchoan · BEACON-HCC Framework · View post ↗
“BEACON-HCC is a MultiD treatment allocation framework for HCC reflecting contemporary practice, w explicit incorporation of SBRT & Y90 based on current evidence.”
— @NiuSanford · BEACON-HCC Framework · View post ↗Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
The IZABRIGHT R3 trial is evaluating the investigational HER1/3 dual-target ADC IzaBren in urothelial carcinoma, based on findings that over 90% of patients express HER1 and HER3. Concurrently, full data from the Phase 3 PSMAddition trial published in The Lancet showed adding 177Lu-PSMA-617 to ADT/ARPI in PSMA-positive metastatic prostate cancer improved radiographic progression-free survival (rPFS HR 0.72), but with more Grade 3+ adverse events and a trend toward worse quality of life during treatment.
“We know most bladder cancers express HER-2 protein, which has become useful ADC target. @scocmem shows >90% of patients also express HER 1 and HER 3 (usually concurrently). This is relevant because the IZABRIGHT R3 trial (enrolling) tests a HER1/3 dual target ADC (IzaBren) in UC.”
— @tompowles1 · New ADC Targets in Bladder Cancer · View post ↗
“RLT moves into earlier stage PCa. But we need to keep an eye on QoL”
— @Adam_Weiner535 · PSMAddition Trial Quality of Life · View post ↗
“The MIBC question is no longer simply “cisplatin eligible or not?” EVP is shifting the map. Now the harder questions begin: Who truly needs intensification? Who can de-escalate? And where does bladder preservation fit?”
— @DrYukselUrun · MIBC Treatment Strategy · View post ↗
“Particularly exciting is the focus on dynamic and functional biomarkers rather than static target expression alone—an area that will be highly relevant for EV and other ADCs in urothelial cancer.”
— @niklas_kluemper · Next-Generation ADCs · View post ↗Three-year follow-up data from the phase 1/2 MonumenTAL-1 trial showed the bispecific antibody talquetamab had a median PFS of 7.5-11.2 months and an OS of 28.3 months to not-reached, with a lower risk of high-grade infections compared to BCMA-targeting TCEs. Additionally, greater than two-year follow-up for teclistamab from the MajesTEC study showed durable responses, with an estimated 30-month duration of response of 80% for patients achieving a complete response or better; a decrease in Grade ≥3 infections was also noted over time, coinciding with less frequent dosing and increased IVIG use.
“Every textbook and manuscript: "Despite the advances in diagnosis and therapy, multiple myeloma remains incurable"”
— @End_myeloma · Prognosis and survivorship · View post ↗
“The next frontier isn’t simply improving response rates—it’s reducing infections, optimizing dosing intervals, and identifying which patients truly benefit from long-term continuous therapy.”
— @Abdallah81MD · Bispecific antibody optimization · View post ↗A revised prognostic model for patients with acute myeloid leukemia at first relapse is slated for publication in Blood Advances on July 28, 2025. Separately, results reported for the upcoming #EHA2026 conference show the investigational combination of favezelimab plus pembrolizumab improved PFS and Duration of Response (DoR) versus chemotherapy in PD-1 refractory Hodgkin lymphoma. Preclinical research in Nature Medicine also described how AML cells invade lung tissue, suggesting new avenues to mitigate respiratory complications.
“A revised prognostic model for patients with acute myeloid leukemia and first relapse [Jul 28, 2025]”
— @mtmdphd · Relapsed AML Prognosis · View post ↗
“favezelimab plus pembrolizumab improved PFS and DoR vs chemotherapy in PD-1 refractory Hodgkin lymphoma, with similar disease control despite lower response rates.”
— @ecancer · Refractory Hodgkin Lymphoma · View post ↗
“Deadly leukemia complications may begin in the lungs. Research featuring @iannisaifantis1 shows how acute myeloid leukemia cells invade lung tissue and impair breathing, pointing to new ways to protect patients during treatment.”
— @nyugrossman · AML Pathophysiology · View post ↗